PSEN1
PSEN1 encodes presenilin 1, the catalytic core of the gamma-secretase complex that cleaves APP and Notch within the membrane. Pathogenic PSEN1 variants are a common cause of autosomal-dominant early-onset Alzheimer disease and often shift amyloid-beta processing toward longer, more aggregation-prone peptides such as Aβ42.
Key Takeaways
- •PSEN1 encodes presenilin 1, the catalytic core of the gamma-secretase protease complex.
- •Pathogenic PSEN1 mutations are a common cause of autosomal-dominant early-onset Alzheimer disease.
- •PSEN1 influences amyloid-beta peptide lengths, including the Aβ42/Aβ40 balance that affects aggregation risk.
- •Gamma-secretase also cleaves Notch, which constrains the safety of direct enzyme inhibition.
Basic Information
- Gene Symbol
- PSEN1
- Full Name
- Presenilin 1
- Also Known As
- PS1AD3
- Location
- 14q24.3
- Protein Type
- Multi-pass membrane protease subunit
- Protein Family
- Presenilin family
Related Isoforms
Key SNPs
Classic high-penetrance mutation associated with autosomal-dominant early-onset Alzheimer disease in large pedigrees.
Well-studied familial Alzheimer disease mutation that shifts gamma-secretase processing toward higher Aβ42/Aβ40.
Aggressive early-onset mutation linked to strong effects on gamma-secretase processivity and Aβ peptide profiles.
Familial Alzheimer disease mutation associated with prominent amyloid pathology and variable clinical phenotypes.
Mutation in a conserved region that can alter cleavage precision and amyloid-beta length distribution.
Reported familial mutation that can perturb presenilin endoproteolysis and complex stability.
Overview
PSEN1 (Presenilin 1) encodes the catalytic core of the gamma-secretase complex, an intramembrane aspartyl protease that cleaves type I membrane proteins within their transmembrane segments. In the brain, gamma-secretase is best known for cleaving APP-derived C99 fragments to generate amyloid-beta peptides, but it also processes Notch and many other substrates involved in signaling and tissue homeostasis.
Pathogenic variants in PSEN1 are a major cause of autosomal-dominant early-onset Alzheimer disease. Many mutations alter processive cleavage, shifting the distribution of amyloid-beta products toward longer peptides such as Aβ42, which are more prone to aggregate and seed downstream pathology.
Conceptual Model
A simplified mental model for the pathway:
Many PSEN1 mutations increase the relative abundance of longer Aβ peptides, increasing aggregation pressure when clearance declines with age.
Core Health Impacts
- • Amyloid balance: Controls intramembrane cleavage of APP and influences amyloid-beta peptide length balance.
- • Notch processing: Processes Notch, linking gamma-secretase biology to essential tissue maintenance pathways.
- • Neuronal signaling: Shapes neuronal signaling through many additional gamma-secretase substrates.
- • Proteostasis: Intersects with proteostasis, lysosomal function, and cellular stress responses in aging.
- • Dementia protection: High-penetrance mutations strongly increase early-onset Alzheimer disease risk.
Protein Domains
Transmembrane core
Multiple transmembrane helices form the catalytic environment for intramembrane proteolysis.
Catalytic aspartates
Two conserved aspartates within the presenilin core are required for protease activity.
Cytosolic loops
Contribute to complex maturation, trafficking, and regulation of cleavage patterns.
Upstream Regulators
Nicastrin Activator
Gamma-secretase subunit that helps recruit and position substrates for intramembrane cleavage.
APH-1 Activator
Scaffold-like subunits that stabilize complex assembly and influence substrate handling.
PEN-2 Activator
Required for presenilin endoproteolysis and maturation of the active complex.
Trafficking Activator
Correct maturation and localization depend on secretory pathway quality control.
Lipids Modulator
Cholesterol and microdomains can modulate localization and substrate access.
Substrate load Modulator
APP C99 and Notch compete for gamma-secretase; abundance influences workload.
Downstream Targets
Aβ profile Activates
PSEN1 influences the balance of Aβ lengths through processive cleavage of APP C99.
NICD Activates
Intramembrane cleavage of Notch releases NICD, a key transcriptional regulator.
AICD Activates
PSEN1-dependent epsilon cleavage releases AICD, influencing gene expression.
Synaptic function Activates
Gamma-secretase activity shapes neuronal signaling through multiple substrates.
Ca2+ homeostasis Activates
PSEN1 mutations are linked to altered ER calcium handling and stress signaling.
Autophagy Activates
Presenilin function intersects with lysosomal function and protein quality control.
Role in Aging
PSEN1 sits at the intersection of peptide production and peptide clearance. Even if total amyloid-beta production changes modestly, a shift toward longer, more aggregation-prone peptides can become increasingly consequential as sleep quality, lysosomal function, and clearance pathways decline with age.
Clearance dependence
Aging-related declines in glymphatic flow and protease capacity make amyloid clearance more rate-limiting over time.
Substrate diversity
Gamma-secretase processes many substrates. This creates biological tradeoffs that constrain therapeutic approaches during aging.
Transport bottlenecks
Blood-brain barrier transport and vascular health influence peptide trafficking and immune clearance of aggregates.
Calcium stress
PSEN1-associated changes in ER calcium handling can interact with aging-related mitochondrial vulnerability.
Tau interaction
Amyloid seeding can accelerate tau pathology, which correlates more strongly with clinical decline.
Proteostasis load
Longer amyloid peptides and aggregates increase the burden on autophagy and lysosomes, which decline with age.
Disorders & Diseases
Early-Onset Alzheimer Disease
PSEN1 mutations are a leading cause of high-penetrance EOAD. A common theme is a shift in processing that increases longer Aβ peptides.
Atypical Phenotypes
Some mutations are associated with prominent seizures, spasticity, or other atypical neurological features.
Notch Toxicity
Broad gamma-secretase inhibition can cause gut and skin toxicity, limiting the therapeutic window.
Proteostasis Failure
Declining lysosomal function with age can amplify the consequences of an aggregation-prone peptide profile.
Metabolic Risk
Insulin resistance and vascular dysfunction can amplify neurodegeneration risk by worsening clearance pathways.
Interventions
Supplements
Support membrane composition and neuroinflammatory balance, influencing amyloid resilience.
Polyphenol studied for anti-aggregation and anti-inflammatory effects relevant to amyloid.
Investigated for effects on neuroinflammation and stress-response pathways that intersect with proteostasis.
May support sleep quality and excitability balance, indirectly supporting cognitive health.
Immune-modulating hormone with associations to cognitive outcomes.
Lifestyle
Deep sleep supports glymphatic clearance and may reduce net accumulation of toxic peptides.
Improves vascular health and metabolic control, supporting clearance and synaptic resilience.
Associated with lower cognitive decline risk and improved cardiometabolic profiles.
Treating hearing and vision loss can reduce cognitive load and support cognitive reserve.
Medicines
Monoclonal antibody targeting amyloid protofibrils to slow cognitive decline in early AD.
Acetylcholinesterase inhibitor used for symptomatic support of cognition in Alzheimer disease.
NMDA receptor antagonist used in moderate to severe AD to reduce excitotoxic stress.
Experimental approach to shift Aβ length distribution without fully blocking Notch processing.
Lab Tests & Biomarkers
Genetic Testing
Clinical sequencing to identify pathogenic missense variants linked to early-onset AD.
Panels often include PSEN1, PSEN2, and APP to cover major autosomal-dominant genes.
Fluid Biomarkers
A lower ratio in spinal fluid indicates amyloid sequestration into brain plaques.
New high-sensitivity blood tests that can accurately predict brain amyloid status.
A blood marker that is highly specific to Alzheimer-related neurodegeneration.
Imaging
Visualizes the burden of amyloid plaques in the living brain using radioactive tracers.
Measures the atrophy of brain regions like the hippocampus following amyloid accumulation.
Hormonal Interactions
Estrogen Neuroprotective
May influence synaptic resilience and shift amyloid processing contextually.
Insulin Metabolic Link
Brain insulin resistance is associated with impaired proteostasis and amyloid clearance.
Cortisol Stress Factor
Chronic elevation can worsen sleep and metabolic control, amplifying neurodegeneration risk.
Melatonin Circadian Lead
Supports sleep architecture, which is linked to brain waste clearance.
Thyroid hormone Metabolic Regulator
Hypothyroidism can worsen cognitive symptoms and affect vascular risk factors.
Deep Dive
Network Diagrams
Gamma-Secretase Complex and Major Substrates
Mutation Effects on Aβ Length Balance
Biological Role: Gamma-Secretase Assembly and Substrate Handling
PSEN1 becomes catalytically active as part of gamma-secretase, a membrane-embedded protease complex. Unlike most proteases, gamma-secretase cuts substrates within the lipid bilayer after an ectodomain has been removed. This is why upstream processing of APP by BACE1 is required before PSEN1 can generate amyloid-beta.
Substrate diversity is the key constraint: gamma-secretase also processes Notch, and Notch signaling is required for tissue maintenance. For this reason, many therapeutic approaches focus on modulation that shifts amyloid-beta length profiles rather than full inhibition.
Processivity and Aβ42 Bias
Gamma-secretase performs stepwise trimming of APP-derived fragments, which determines the distribution of Aβ peptide lengths. Many PSEN1 mutations reduce efficient trimming, increasing the relative abundance of longer peptides such as Aβ42 that are more aggregation-prone.
Why ratios matter: aggregation and seeding are nonlinear. If clearance systems are stressed, even a modest shift toward longer peptides can increase downstream plaque and tau pathology risk over time.
Notch Processing Creates a Therapeutic Tradeoff
Notch is an essential gamma-secretase substrate. When gamma-secretase is broadly inhibited, Notch signaling drops, which can produce predictable toxicity in the gut and skin and can perturb immune function.
Implication: therapies that fully block gamma-secretase have a narrow therapeutic window. Approaches that modulate cleavage to reduce long Aβ peptides while preserving Notch processing are conceptually attractive.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
Identified PSEN1 as a major gene for autosomal-dominant early-onset Alzheimer disease.
Genetic evidence that presenilin-1 is required for gamma-secretase cleavage of APP.
Demonstrated presenilin dependence of both APP and Notch intramembrane proteolysis.
Defined the core gamma-secretase complex subunits and their functional coassembly.